Tinospora cordifolia (Willd.) Hook.f. & Thomson, commonly called Guduchi or Giloy, is a medicinal climber of the Menispermaceae family. Ayurveda classifies its stem as a Rasayana, a restorative drug used within broader, individually selected treatment plans. Experimental pharmacology has identified several immune-related actions, but human clinical evidence remains limited, and documented liver injury makes unsupervised or prolonged use inappropriate.

Botanical Identity and Ayurvedic Profile

The currently accepted botanical name is Tinospora cordifolia (Willd.) Hook.f. & Thomson, although the Ayurvedic Pharmacopoeia of India uses the older author citation Tinospora cordifolia (Willd.) Miers. It is a perennial liana native from the Indian subcontinent to Indo-China. The official Ayurvedic drug Guduchi consists primarily of dried, mature stem pieces; the fresh stem may also be used in traditional pharmaceutical preparation.

The Ayurvedic Pharmacopoeia describes the stem through the following properties:

  • Rasa: Tikta and Kashaya—bitter and astringent tastes
  • Guna: Laghu—light quality
  • Virya: Ushna—heating potency
  • Vipaka: Madhura—sweet post-digestive effect
  • Karma: Rasayana, Balya, Dipana, Sangrahi, Raktashodhaka, Jvaraghna and Tridoshashamaka

Officially listed Ayurvedic uses include conditions described as Jvara, Kushtha, Pandu, Prameha, Vatarakta and Kamala. These Sanskrit diagnostic categories should not be treated as exact substitutes for modern biomedical diagnoses. Guduchi is also an ingredient in formulations such as Amritarishta, Amritottara Kvatha Churna, Guduchi Sattva, Guduchyadi Churna and Chinnodbhavadi Kvatha Churna.

Pharmacognosy and Phytochemical Profile

Guduchi stem develops a green surface when young and a light-brown, corky surface with prominent lenticels as it matures. Pharmacopoeial identification combines macroscopic and microscopic examination with physicochemical limits rather than relying on a single marker compound. The Ayurvedic Pharmacopoeia sets limits for foreign matter, total ash and acid-insoluble ash, together with minimum alcohol-soluble and water-soluble extractive values.

Investigations of T. cordifolia have reported chemically diverse constituents, including clerodane-type diterpenoids, alkaloids, glycosides, steroids, phenolic compounds and polysaccharides. Named constituents described in analytical literature include tinosporide, tinosporaside, cordifoliosides, magnoflorine and berberine. Their presence and concentration vary according to plant part, geographical source, maturity, extraction solvent and manufacturing process.

Individual compounds should not be assigned the therapeutic activity of the complete herb without preparation-specific evidence. A water extract rich in polysaccharides is chemically different from an alcohol extract enriched in less-polar constituents, while Guduchi Sattva is a traditional starch-rich preparation with its own method of manufacture. Results obtained with one preparation therefore cannot automatically determine the effects or dosage of another commercial product.

Experimental Immunomodulation

Much of Guduchi’s modern immune-related dossier comes from cell and animal experiments. These models describe biological activity and possible mechanisms, but they do not establish that routine consumption will “boost immunity” or prevent infection in humans. The direction and magnitude of an effect depend on the extract, concentration, test system and disease model.

A purified arabinogalactan polysaccharide designated G1-4A altered nitric-oxide and cytokine responses in macrophage systems and protected mice in an experimental endotoxin model. Separate in-vitro work with an aqueous stem extract reported enhanced phagocytosis and pinocytosis in macrophage-like cells. Later experiments found that some G1-4A responses were dependent on Toll-like receptor 4 signalling in macrophage and mouse models.

Other laboratory investigations have described anti-inflammatory effects involving inflammatory mediators and T-cell responses. These observations do not support a universal rule that Guduchi stimulates immunity at one dose and suppresses it at another. They instead indicate preparation-specific immunological activity that requires clinical interpretation, particularly in people with autoimmune disease, organ transplants or treatment that intentionally suppresses immune function.

Human Clinical Evidence

Human evidence consists mainly of small trials using specific extracts for defined periods. It is insufficient to treat Guduchi as a generally proven therapy for immune deficiency, viral illness, diabetes, arthritis, liver disease or cancer. Outcomes from experimental models should not be substituted for controlled clinical results.

In a randomized, double-blind, placebo-controlled allergic-rhinitis trial, 75 adults were assigned to a standardized aqueous stem extract or placebo for eight weeks, and 71 completed the study. The active preparation contained 300 mg of extract per tablet and was taken three times daily. The Guduchi group reported greater improvement in sneezing, nasal discharge, nasal obstruction and nasal itching. A few participants reported nasal pain or headache, and the trial was too small to establish broad long-term safety.

A separate randomized, double-blind, placebo-controlled trial enrolled 68 people living with HIV and administered a T. cordifolia extract or placebo for six months. More participants receiving the extract reported relief from disease-associated symptoms, but objective laboratory measurements, including CD4-cell outcomes, did not consistently demonstrate the claimed immunological benefit. This trial does not support replacing antiretroviral therapy or using Guduchi as a treatment for HIV infection.

Clinical claims concerning glucose control, inflammatory disease and liver protection are often based on animal experiments, uncontrolled observations or small heterogeneous studies. They do not provide a universally validated extract, treatment duration or dose. This distinction is especially important because the herb has also been associated with clinically significant liver injury.

Study Comparison

The following table separates official pharmacopoeial information, experimental mechanisms, small clinical trials and safety surveillance. Evidence from these categories answers different questions and should not be combined as though it had equal clinical weight.

Reference Evidence Type Preparation or Exposure Primary Observation Interpretation
Ayurvedic Pharmacopoeia of India, Part I, Vol. I Official monograph Dried mature Guduchi stem Identity, purity, Ayurvedic properties, uses and dose Authoritative pharmacopoeial standard for the crude Ayurvedic drug
PMID 17673153 Macrophage and mouse experiments Purified arabinogalactan polysaccharide G1-4A Modulation of macrophage responses and protection in an endotoxin model Preclinical mechanism; not proof of a human indication
PMID 30183225 In-vitro experiment Aqueous T. cordifolia extract Enhanced phagocytosis and pinocytosis Cell-level activity dependent on the tested extract and model
PMID 15619563 Randomized double-blind trial 300 mg aqueous stem extract three times daily for eight weeks Improvement in several allergic-rhinitis symptoms Promising small trial requiring independent replication
PMID 20040936 Randomized double-blind trial T. cordifolia extract for six months in 68 people with HIV Some symptom improvement without consistent objective immune benefit Does not establish efficacy for HIV or justify replacing standard care
PMID 35037744 Multicentre liver-injury series Giloy-containing products Acute hepatitis, frequently with autoimmune features Clinically important safety signal, especially with underlying liver disease

Immunomodulation Pathway Diagram

This diagram summarizes experimentally described pathways rather than established clinical effects. The findings apply to the particular extracts, isolated polysaccharides, cells and animal models in which they were measured.

T. CORDIFOLIA: EXPERIMENTAL IMMUNE PATHWAYS
MACROPHAGE FUNCTION
Aqueous preparations have enhanced phagocytosis and pinocytosis in cell-based experiments.

POLYSACCHARIDE SIGNALLING
G1-4A has altered nitric-oxide and cytokine responses, with TLR4-dependent activity in experimental models.

INFLAMMATORY RESPONSES
Extract-dependent effects on inflammatory mediators and T-cell responses have been described in laboratory models.

These pathways do not establish a general immune-boosting dose, preventive benefit or clinical indication in humans.

Safety Profile and Drug Interactions

Guduchi should not be described as universally safe merely because it is traditional or plant-derived. Published reports and multicentre clinical series have associated T. cordifolia products with acute liver injury. The usual pattern has been hepatocellular hepatitis, often accompanied by autoantibodies or other autoimmune features, rather than simple contamination-related cholestasis.

In a 43-patient multicentre Indian series, Giloy-associated injury included acute hepatitis, acute worsening of pre-existing chronic liver disease and a smaller number of acute liver-failure presentations. Some patients died or required liver transplantation. Botanical and analytical investigations have also identified authentic T. cordifolia in implicated material, so substitution with Tinospora crispa cannot account for every reported case.

People with existing liver disease, previous unexplained hepatitis or suspected autoimmune hepatitis should avoid self-prescribing Guduchi. Use should be stopped and medical assessment sought promptly if jaundice, dark urine, persistent nausea, marked fatigue, loss of appetite or generalized itching develops.

Because experimental and clinical literature describes effects on immune function and blood glucose, additional caution is appropriate for people with autoimmune disorders, organ transplants, immunosuppressive treatment or glucose-lowering medication. Combining Guduchi with insulin or oral diabetes medicines may complicate glucose management. Reliable safety information is also insufficient for pregnancy and breastfeeding.

Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before using Guduchi, particularly when prescription medicines are being taken. It must not replace vaccination, antimicrobial treatment, antiretroviral therapy, diabetes care, liver-disease management or any other medically indicated treatment.

Dosage and Standardization

The Ayurvedic Pharmacopoeia lists 3–6 g of stem powder and 20–30 g of crude stem drug for preparing a decoction. These are pharmacopoeial ranges for the identified crude drug, not universal instructions for every patient or product. Classical prescribing also considers formulation, digestive capacity, age, constitution, disease stage, accompanying herbs and the intended method of administration.

There is no single clinically validated conversion between crude stem, powder, fresh stem, decoction, Guduchi Sattva and concentrated commercial extracts. A label such as “10:1 extract” does not by itself establish equivalence, because extraction yield and retained constituents depend on manufacturing conditions. The 300 mg three-times-daily regimen used in the allergic-rhinitis trial applies only to that standardized aqueous extract and should not be generalized to other products.

Quality assessment should begin with correct botanical identity and the plant part specified on the label. Pharmacopoeial testing includes microscopy, foreign-matter limits, ash values and solvent-extractive values. Chemical markers can assist batch characterization, but a marker result alone does not prove therapeutic equivalence, freedom from adulteration or absence of liver risk.

Conclusion

Guduchi has a clearly documented place in the Ayurvedic materia medica, with official rasa, guna, virya, vipaka, actions, formulations and crude-drug standards. Its polysaccharides and extracts display substantial immune-related activity in experimental systems, while limited human trials provide preliminary findings for selected preparations rather than broad proof of efficacy.

The modern safety record requires equal emphasis. Authentic Tinospora cordifolia has been associated with serious, sometimes autoimmune-like liver injury, and product-to-product variation prevents universal extract dosing. Guduchi is therefore best treated as a potent medicinal substance requiring proper identification, individualized Ayurvedic assessment and coordination with qualified healthcare professionals.

References

  1. Powo (powo.science.kew.org)
  2. Ayurvedic Pharmacopoeia of India
  3. Tinospora Cordifolia: A review of its immunomodulatory properties (2022), PubMed
  4. The chemical constituents and diverse pharmacological importance of Tinospora cordifolia (2019), PubMed Central
  5. Indian herb Tinospora cordifolia and Tinospora species: Phytochemical and therapeutic application (2024), PubMed Central
  6. G1-4A, an immunomodulatory polysaccharide from Tinospora cordifolia, modulates macrophage responses and protects mice against lipopolysaccharide induced endotoxic shock (2007), PubMed
  7. Effect of Tinospora cordifolia (Guduchi) on the phagocytic and pinocytic activity of murine macrophages in vitro (2017), PubMed
  8. Journals (journals.plos.org)
  9. Frontiersin (frontiersin.org)
  10. Efficacy of Tinospora cordifolia in allergic rhinitis (2005), PubMed
  11. Lehvoss-nutrition (lehvoss-nutrition.com)
  12. Immunomodulatory effect of Tinospora cordifolia extract in human immuno-deficiency virus positive patients (2008), PubMed
  13. Immunomodulatory effect of Tinospora cordifolia extract in human immuno-deficiency virus positive patients (2008), PubMed Central
  14. NCBI
  15. Tinospora Cordifolia (Giloy)-Induced Liver Injury During the COVID-19 Pandemic-Multicenter Nationwide Study From India (2022), PubMed
  16. Tinospora Cordifolia (Giloy)-Induced Liver Injury During the COVID-19 Pandemic-Multicenter Nationwide Study From India (2022), PubMed Central
  17. Herb-induced Liver Injury-A Guide to Approach. Lessons from the Tinospora cordifolia (Giloy) Case Series Story (2023), PubMed Central
  18. Webmd (webmd.com)
  19. Rxlist (rxlist.com)